Utrogestan Vaginal Capsules Approved and Launched
First written in FY2016-Q3. 17 of 19 entries say "Cited as achieved", first in FY2017-Q1. Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3Cited as achievedAnnual report
「In the women’s healthcare area, we are focusing on sales of Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms, and Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology and listed in the National Health Insurance drug price list in April 2022 as a drug used in infertility treatment,」
Continues to identify Femeno capsules 100 mg and Utrogestan vaginal capsules 200 mg, listed in the National Health Insurance drug price list in April 2022, as priority products for sales in women’s healthcare. - FY2023-Q1Cited as achievedAnnual report
「In the women’s healthcare area, we are focusing on sales of Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms, and Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology and listed in the National Health Insurance drug price list in April 2022 as a drug used in infertility treatment,」
Cites the April 2022 listing of Utrogestan vaginal capsules 200 mg in the National Health Insurance drug price list as a past achievement and states that sales efforts remain a priority. - FY2022-Q1Cited as achievedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Cites the 2016 manufacturing and marketing approval as a past achievement and states that sales efforts for Utrogestan vaginal capsules 200 mg remain a priority. - FY2021-Q3Cited as achievedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Restates the 2016 manufacturing and marketing approval as a past achievement and states that sales efforts for Utrogestan vaginal capsules 200 mg remain a priority. - FY2021-Q2Cited as achievedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Restates the 2016 manufacturing and marketing approval as a past achievement and states that sales efforts for Utrogestan vaginal capsules 200 mg remain a priority. - FY2021-Q1Cited as achievedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Restates the 2016 manufacturing and marketing approval as a past achievement and states that sales efforts for Utrogestan vaginal capsules 200 mg remain a priority during the current quarter. - FY2020-Q3Cited as achievedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Restates the 2016 manufacturing and marketing approval as a past achievement and states that sales efforts for Utrogestan vaginal capsules 200 mg remain a priority. - FY2020-Q2Cited as achievedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Restates the 2016 manufacturing and marketing approval as a past achievement and states that sales efforts for Utrogestan vaginal capsules 200 mg remain a priority. - FY2019-Q3Cited as achievedAnnual report
「While focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Cites the manufacturing and marketing approval obtained in 2016 as a past achievement and states that sales efforts remained a priority during the current quarter. - FY2019-Q2Cited as achievedAnnual report
「While focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Cites the manufacturing and marketing approval obtained in 2016 as a past achievement and states that sales efforts remained a priority during the current quarter. - FY2019-Q1Cited as achievedAnnual report
「While focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Cites the approval obtained in 2016 as a past achievement and states that sales efforts remained a priority during the current quarter. - FY2018-Q3Cited as achievedAnnual report
「While focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Cites the manufacturing and marketing approval obtained in 2016 as a past achievement and states that sales efforts remained a priority during the current quarter. - FY2018-Q2Cited as achievedAnnual report
「While focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Cites the manufacturing and marketing approval obtained in 2016 as a past achievement and states that sales efforts remained a priority during the current quarter. - FY2018-Q1Cited as achievedAnnual report
「While focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Cites the approval obtained in 2016 as a past achievement and states that sales efforts remained a priority during the current quarter. - FY2017AdvancedAnnual report
「Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology and launched in February 2016, increased by ¥324 million.」
States that sales efforts remained a priority and that sales for the fiscal year increased by ¥324 million. - FY2017-Q3Cited as achievedAnnual report
「While focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Cites the first manufacturing and marketing approval obtained in 2016 as a past achievement and states that sales efforts remained a priority during the current quarter. - FY2017-Q2Cited as achievedAnnual report
「While focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Cites the first manufacturing and marketing approval obtained in 2016 as a past achievement and states that sales efforts remained a priority during the current quarter. - FY2017-Q1Cited as achievedAnnual report
「While focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016,」
Cites the 2016 manufacturing and marketing approval as a past achievement and states that sales efforts remained a priority during the current quarter. - FY2016-Q3First statedAnnual report
「On 22 January 2016, we obtained manufacturing and marketing approval for Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, and commenced sales.」
Describes the specific product rollout, including obtaining manufacturing and marketing approval and commencing sales.